Overview

Study of AMG 650 in Adult Participants With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2024-07-02
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Phase:
Phase 1
Details
Lead Sponsor:
Amgen